Massa T, Sinha D P, Frantz J D, Filipek M E, Weglein R C, Steinberg S A, McGrath J T, Murphy B F, Szot R J, Black H E
Fundam Appl Toxicol. 1985 Aug;5(4):737-53. doi: 10.1016/0272-0590(85)90198-8.
Two subchronic studies were conducted to assess the potential toxicity of N-D-ornithyl amphotericin B methyl ester (OAME). In both studies the comparative control substance was amphotericin B (AMB). Dogs (5/sex/group) were given OAME (82% pure, based on high-pressure liquid chromatographic (HPLC) analysis) at 0.6, 2.5, and 10 mg/kg or AMB at 0.6 mg/kg intravenously once daily for 3 months. Two dogs per sex per group were retained for a 7-week postdose observation period. Rats (15/sex/group) were given daily doses of OAME at 4, 12, 24, and 36 mg/kg or AMB at 5 and 12 mg/kg intraperitoneally for 3 months. The principal organs of toxicity in both species were the liver, kidneys, and circulating erythrocytes. Hepatic changes in dogs consisted of periportal and centrilobular inflammation in animals of all dosed groups and were equivalent in dogs given 0.6 mg/kg OAME or AMB. In rats, acute hepatic necrosis with periportal, centrilobular, or panlobular distribution in animals of all OAME (except 4 mg/kg) and AMB-dosed groups was observed. These changes were equivalent in the 36-mg/kg OAME- and 12-mg/kg AMB-dosed animals. Renal changes, evidenced by increases in serum urea nitrogen water consumption, urine volume, decreased urine osmolality, and renal tubular changes (ranging from degeneration and regeneration to necrosis), were observed in both species. In dogs, these changes in the OAME-dosed animals were less severe at all doses than those observed in the AMB-dosed dogs. Renal changes in rats, which were mild in comparison to the dogs, were equivalent at doses of 5 and 12 mg/kg AMB and 36 mg/kg OAME. Decreased erythrocyte counts, hematocrit, and hemoglobin values were observed in both species. Unique to the dog study, however, were irreversible behavioral (somnolence, ataxia, tremors, and compulsive searching) and/or morphologic brain changes (gliosis with astrocytic hypertrophy and hyperplasia) at doses of 2.5 and 10 mg/kg OAME. Similar changes were observed in two dogs given 10 mg/kg OAME (100% pure, based on HPLC analysis) in a 6-week pilot study, indicating that the neurological changes were induced by OAME rather than by an impurity. These changes appear related to prolonged exposure to high plasma concentrations of OAME.
进行了两项亚慢性研究,以评估N-D-鸟氨酰两性霉素B甲酯(OAME)的潜在毒性。在这两项研究中,比较对照物质均为两性霉素B(AMB)。犬(每组5只/性别)静脉注射纯度为82%(基于高压液相色谱(HPLC)分析)的OAME,剂量分别为0.6、2.5和10mg/kg,或静脉注射AMB,剂量为0.6mg/kg,每日一次,持续3个月。每组每种性别保留2只犬进行7周的给药后观察期。大鼠(每组15只/性别)腹腔注射OAME,剂量分别为4、12、24和36mg/kg,或注射AMB,剂量为5和12mg/kg,持续3个月。两个物种的主要毒性器官均为肝脏、肾脏和循环红细胞。犬的肝脏变化包括所有给药组动物的门静脉周围和小叶中心炎症,在给予0.6mg/kg OAME或AMB的犬中相当。在大鼠中,观察到所有OAME(4mg/kg除外)和AMB给药组动物出现急性肝坏死,坏死呈门静脉周围、小叶中心或全小叶分布。在给予36mg/kg OAME和12mg/kg AMB的动物中,这些变化相当。两个物种均观察到肾脏变化,表现为血清尿素氮饮水量增加、尿量增加、尿渗透压降低以及肾小管变化(从变性和再生到坏死)。在犬中,所有剂量的OAME给药动物的这些变化均比AMB给药犬观察到的变化轻。与犬相比,大鼠的肾脏变化较轻,在给予5和12mg/kg AMB以及36mg/kg OAME时相当。两个物种均观察到红细胞计数、血细胞比容和血红蛋白值降低。然而,在犬的研究中,独特的是在给予2.5和10mg/kg OAME时出现不可逆的行为(嗜睡、共济失调、震颤和强迫性搜寻)和/或形态学脑变化(伴有星形细胞肥大和增生的胶质增生)。在一项为期6周的预试验研究中,给予10mg/kg OAME(基于HPLC分析为100%纯品)的两只犬也观察到了类似变化,表明神经学变化是由OAME而非杂质引起的。这些变化似乎与长时间暴露于高血浆浓度的OAME有关。